NEKTAR THERAPEUTICS Quarterly Operating Income (Loss) in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Nektar Therapeutics quarterly/annual Operating Income (Loss) history and growth rate from Q1 2010 to Q3 2024.
  • Nektar Therapeutics Operating Income (Loss) for the quarter ending September 30, 2024 was -$34.3M, a 23.4% increase year-over-year.
  • Nektar Therapeutics Operating Income (Loss) for the twelve months ending September 30, 2024 was -$153M, a 45.8% increase year-over-year.
  • Nektar Therapeutics annual Operating Income (Loss) for 2023 was -$264M, a 29.9% increase from 2022.
  • Nektar Therapeutics annual Operating Income (Loss) for 2022 was -$376M, a 15.7% increase from 2021.
  • Nektar Therapeutics annual Operating Income (Loss) for 2021 was -$446M, a 4.94% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$153M -$34.3M +$10.5M +23.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 -$164M -$49.8M +$825K +1.63% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$164M -$35.4M +$99.3M +73.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 -$264M -$33.5M +$19M +36.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 -$283M -$44.9M +$9.44M +17.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 -$292M -$50.6M +$102M +66.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$394M -$135M -$18.2M -15.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$376M -$52.5M +$60.4M +53.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$437M -$54.3M +$59.3M +52.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$496M -$153M -$42.6M -38.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$453M -$117M -$7.17M -6.55% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$446M -$113M -$2.19M -1.98% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-01
Q3 2021 -$444M -$114M -$10.5M -10.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 -$433M -$110M -$32.5M -41.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 -$401M -$109M +$24.2M +18.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 -$425M -$111M -$1.08M -0.99% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$424M -$103M -$4.31M -4.37% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-01
Q2 2020 -$420M -$77.7M +$33.3M +30% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-01
Q1 2020 -$453M -$134M -$12.9M -10.7% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-01
Q4 2019 -$440M -$110M -$9.34M -9.32% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-26
Q3 2019 -$431M -$98.7M -$106K -0.11% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-26
Q2 2019 -$431M -$111M -$1.08B -111% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-26
Q1 2019 $654M -$121M -$33.9M -39.1% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-26
Q4 2018 $688M -$100M -$76.3M -317% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 $764M -$98.6M -$168M -242% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-28
Q2 2018 $932M $974M +$1.02B Apr 1, 2018 Jun 30, 2018 10-K 2020-02-28
Q1 2018 -$91.9M -$86.7M -$32.3M -59.3% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-28
Q4 2017 -$59.6M -$24M +$8.11M +25.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 -$67.8M $69.5M +$102M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 -$170M -$50.7M -$12.3M -32.2% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 -$158M -$54.4M -$45M -474% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
Q4 2016 -$113M -$32.1M -$2.78M -9.47% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$110M -$32.9M -$33.3M -7952% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$76.8M -$38.3M +$5.14M +11.8% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$81.9M -$9.48M -$52.5M -122% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 -$29.4M -$29.4M +$8.12M +21.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 -$37.5M $419K -$79.9M -99.5% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 $42.4M -$43.5M -$20.6M -89.7% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 $63M $43M +$79.4M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
Q4 2014 -$16.5M -$37.5M -$1.59M -4.44% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-01
Q3 2014 -$14.9M $80.3M +$86.8M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-01
Q2 2014 -$102M -$22.9M +$9.69M +29.7% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-01
Q1 2014 -$111M -$36.4M +$8.7M +19.3% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-01
Q4 2013 -$120M -$35.9M +$7.49M +17.3% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-26
Q3 2013 -$128M -$6.53M +$26.4M +80.2% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-26
Q2 2013 -$154M -$32.6M -$5.62M -20.8% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-26
Q1 2013 -$148M -$45.1M -$7.17M -18.9% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-26
Q4 2012 -$141M -$43.4M -$8.91M -25.9% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-27
Q3 2012 -$132M -$32.9M -$11.6M -54.2% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-27
Q2 2012 -$121M -$27M +$7.28M +21.2% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-27
Q1 2012 -$128M -$37.9M -$4.07M -12% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-27
Q4 2011 -$124M -$34.5M -$13.9M -67.8% Oct 1, 2011 Dec 31, 2011 10-K 2013-03-01
Q3 2011 -$110M -$21.3M -$15.1M -243% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-01
Q2 2011 -$94.9M -$34.3M -$36.1M -1935% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-01
Q1 2011 -$58.8M -$33.9M -$30.5M -909% Jan 1, 2011 Mar 31, 2011 10-K 2013-03-01
Q4 2010 -$28.3M -$20.5M Oct 1, 2010 Dec 31, 2010 10-K 2012-02-29
Q3 2010 -$6.23M Jul 1, 2010 Sep 30, 2010 10-K 2012-02-29
Q2 2010 $1.87M Apr 1, 2010 Jun 30, 2010 10-K 2012-02-29
Q1 2010 -$3.36M Jan 1, 2010 Mar 31, 2010 10-K 2012-02-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.